The value of progesterone and estrogen receptors expression in tissue microarray method in prognosis of patients with endometrioid endometrial cancer;Znaczenie ekspresji receptorów progesteronowych i estrogenowych ocenianej metodą mikromacierzy tkankowych dla rokowania u chorych z gruczolakorakiem endometrioidalnym endometrium

Ginekologia Polska

Volumn 84, Issue 2, 2013, Pages 95-101

  Leszek, Gottwald ^a,b   Robert, Kubiak ^a   Grazyna, Pasz Walczak ^a   Piotr, Sek ^a   Janusz, Piekarski ^a   Jarosław, Szwalski ^c   Michał, Spych ^a,d   Justyna, Chałubińska Fendler ^a,b   Jacek, Suzin ^a   Wiesław, Tyliński ^a   Arkadiusz, Jeziorski ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Wojewódzki Specjalistyczny Szpital im M Kopernika w odzi   (Poland)

^c Olympus Consilio Sp z OO w odzi   (Poland)

^d Wojewódzki Specjalistyczny Szpital im M Kopernika w odzi   (Poland)

Author keywords

Endometrial cancer; Endometrioid carcinoma; Estrogen receptor; Progesterone receptor; Prognosis; Tissue microarrays

Indexed keywords

EID: 84875509731     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Zakład Epidemiologii i Prewencji Nowotworów Centrum Onkologii-Instytut w Warszawie. Krajowa baza danych nowotworowych. http://www.onkologia.org.pl
2. Benedet J, Bender H, Jones H 3 rd, [et al.]. FIGO staging classifications and clinical practice guidelines for gynaecological cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obsetet. 2000, 70, 209-262.
3. Pecorelli S, Denny L, Ngan H, [et al.]. The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas. Gynecol Oncol. 2009, 115, 325-328.
4. Gehrig P, Van Le L, Olatidoye B, Geradts J. Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma. J Cancer. 1999, 86, 2083-2089.
5. Hirai M, Hirono M, Oosaki T, [et al.]. Prognostic factors relating to survival in uterine endometrioid carcinoma. Int J Gynaecol Obstet. 1999, 66, 155-162.
6. Chakravarty D, Gupta N, Goda J, [et al.]. Steroid receptors HER2/neu and Ki 67, in endometrioid type of endometrial carcinoma: correlation with conventional histomorphological features of prognosis. Acta Histochem. 2010, 112, 355-363.
7. Markova I, Duskova M, Lubusky M, [et al.]. Selected immunohistochemical prognostic factors in endometrial cancer. Int J Gynecol Cancer. 2010, 20, 576-582.
8. Srijaipracharoen S, Tangjitgamol S, Tanvanich S, [et al.]. Expression of ER, PR, and Her-2/neu in endometrial cancer: a clinicopathological study. Asian Pac J Cancer Prev. 2010, 11, 215-220.
9. Kononen J, Bubendorf L, Kallioniemi A, [et al.]. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998, 4, 844-847.
10. Jongen V, Briët J, de Jong R, [et al.]. Expression of estrogen receptor-alpha and-beta and progesterone receptor-A and-B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol. 2009, 112, 537-542.
11. Cimbaluk D, Rotmensch J, Scudiere J, [et al.]. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. Gynecol Oncol. 2007, 105, 138-144.
12. Huang G, Arend R, Li M, [et al.]. Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma. Am J Obstet Gynecol. 2009, 200, 457.e1-5.
13. Allred D, Harvey J, Bernardo M, Clark G. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998, 11, 155-168.
14. Kurman R, Kalminski P, Norris H. The behavior of endometrial hyperplasia: a long term study of "untreated" hyperplasia in 170 patients. Cancer. 1985, 56, 403-412.
15. Yang S, Thiel K, Leslie K. Progesterone: the ultimate endometrial tumor suppressor. Trends Endocrinol Metab. 2011, 22, 145-152.
16. Sherman M. Theories of endometrial carcinogenesis: a multidisciplinary approach. Modern Pathol. 2000, 13, 295-308.
17. Jeon Y, Part I, Kim Y, [et al.]. Steroid receptor expressions in endometrial cancer: clinical significance and epidemiological implication. Cancer Lett. 2006, 239, 198-204.
18. Stoian S, Simionescu C, Mǎrgǎritescu C, [et al.]. Endometrial carcinomas: correlation between ER, PR, Ki67 status and histopathological prognostic parameters. Rom J Morphol Embryol. 2011, 52, 631-636.
19. Fokuda K, Mori M, Uchiyama M, [et al.]. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol Oncol. 1998, 69, 220-225.
20. Hanekamp E, Ku{double acute}hne E, Smid-Koopman E, [et al.]. Loss of progesterone receptor may lead to an invasive phenotype in human endometrial cancer. Eur J Cancer. 2002, 38, Suppl.6, 71-72.
21. Chambers J, Carcangiu M, Voynick I, Schwartz P. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Am J Clin Pathol. 1990, 94, 255-260.
22. Creasman W. Prognostic significance of hormone receptors in endometrial cancer. Cancer. 1993, 71, 1467-1470.
23. Shabani N, Kuhn C, Kunze S, [et al.]. Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer. 2007, 43, 2434-2444.
24. Pertshuk L, Masood S, Simone J, [et al.]. Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival. Gynecol Oncol. 1996, 63, 8-33.
25. Gottwald L, Se{ogonek}k P, Kubiak R, [i wsp.]. Efektywność zastosowania techniki mikromacierzy tkankowych do oceny ekspresji receptorow estrogenowych i progesteronowych w gruczolakoraku endometrioidalnym endometrium-doniesienie wste{ogonek}pne. Ginekol Pol. 2012, 83, 342-346.
26. Mirlacher M, Simon R. Recipient block in TMA technique. Methods Mol Biol. 2010, 664, 37-44.
27. Shergill I, Shergill N, Araya M, [et al.]. Tissue microarrays: a current medical research tool. Curr Med Res Opin. 2004, 20, 707-712.
28. Voduc D, Kenney C, Nielsen T. Tissue microarrays in clinical oncology. Semin Radiat Oncol. 2008, 18, 89-97.
29. Takikita M, Chung J, Hewitt S. Tissue microarrays enabling high-throughput molecular pathology. Curr Opin Biotechnol. 2007, 18, 318-325.
30. Hassan S, Ferrario C, Mamo A, Basik M Tissue microarrays: emerging standard for biomarker validation. Curr Opin Biotechnol. 2008, 19, 19-25.